The Pasinetti Lab is focused on the prevention of Alzheimer’s disease and cognitive deterioration in the aging population, even before the disease becomes symptomatic. Dr. Pasinetti’s lab embraces preclinical investigations with a final goal of translating studies into the clinical setting. Based on ongoing genomic and metabolomic studies, the laboratory is focusing on characterization of novel molecular biomarkers of disease allowing for the design of novel drug discovery program, as well as repurposing drugs and natural compounds to improve therapeutic efficacy by leveraging on the gut microbiome’s role in promoting cognitive and psychological  resilience in response to stressful conditions.